A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Key facts

Sponsor

Hoffmann-La Roche

Principal Investigator

Clinical Trials

Hoffmann-LaRoche

Intervention

Tobemstomig(drug)

Enrollment

199 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• UC Irvine Medical Center, Orange, California, United States
• Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
• Emory University, Atlanta, Georgia, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
• SCRI Oncology Partners, Nashville, Tennessee, United States
• Vanderbilt University Medical Center, Nashville, Tennessee, United States
• UT Southwestern Medical Center, Dallas, Texas, United States
• Sunshine Coast University Hospital, Birtinya, Queensland, Australia
• Peking University First Hospital, Beijing, China
• Beijing Cancer Hospital, Beijing, China
• Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China
• Tianjin Cancer Hospital, Tianjin, China
• Institut Sainte Catherine, Avignon, France
• CHU Besançon - Hôpital Jean Minjoz, Besançon, France
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chromophobe renal cell carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07485114
  Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
  Daniel Keizman
• RECRUITINGPHASE3NCT07227402
  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT07233252
  Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
  Tianjin Medical University Second Hospital
• RECRUITINGNANCT07171190
  Targeted Abdominal CT in Conjunction With Lung Cancer Screening
  University of Cambridge
• RECRUITINGPHASE2NCT07050771
  Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
  The Methodist Hospital Research Institute
• RECRUITINGPHASE2NCT06642220
  Ablative Radioembolization of Renal Cell Carcinoma Trial
  Derek W. Cool
• RECRUITINGNCT06889974
  Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
  University Hospital, Bordeaux
• ENROLLING BY INVITATIONNCT07307157
  Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only Review
  Harvard Medical School (HMS and HSDM)

See all trials for Chromophobe renal cell carcinoma →